Quantcast
Last updated on April 24, 2014 at 13:57 EDT

Latest Immunosuppressive drug Stories

2008-08-12 12:00:34

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount. The Phase 2A clinical trial is...

2008-07-30 09:01:27

WASHINGTON, July 30 /PRNewswire-FirstCall/ -- The ability of blood tests to precisely measure very low doses of anti-rejection drugs in kidney transplant patients may make a significant difference in assuring long-term viability and survival, according to research presented today at the American Association for Clinical Chemistry (AACC) annual meeting. The current thinking in transplant medicine favors reducing doses of tacrolimus and other immune-suppressive drugs as much as possible...

2008-07-09 09:00:12

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant...

2008-07-03 15:00:10

Chinese scientists say a treatment using several drugs targeting various parts of the immune system helps patients with severe lupus involving the kidneys. In our study, multitarget therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects, said Dr. Lei-Shi Li of the University School of Medicine in Nanjing, China. Lupus nephritis is inflammation of the kidneys occurring in patients with systemic lupus...

2008-06-01 18:00:06

TORONTO, June 1 /PRNewswire/ -- The final results of the Spare the Nephron (STN) study, a multicenter trial investigating a novel kidney-sparing treatment protocol using CellCept(R) (mycophenolate mofetil), showed the CellCept-based regimen in combination with sirolimus (SRL) is associated with improved renal function when compared with the CellCept-based regimen in combination with calcineurin inhibitors (CNI). Furthermore, the study showed this improvement without increasing the risk of...

2008-01-23 06:00:54

Reportlinker.com announces that a new market research report related to the Health Care industry is available in its catalogue. Organ Transplant Immunosuppressive Markets To order that report: www.reportlinker.com/p075365/Organ-Transplant- Immunosuppressive-Markets.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) For more information, contact Nicolas by email nbo@reportlinker.com ,...

2006-10-25 21:00:35

Four Boston doctors had their research regarding the treatment of autoimmune disease reported in this week's New England Journal of Medicine (NEJM). Specifically Drs. Abdul Razzaque Ahmed, Zachary Spigelman, Lisa Cavacini and Marshall Posner reported on their use of rituximab and intravenous immune globulin in patients with recalcitrant pemphigus vulgaris. Pemphigus vulgaris is a potentially fatal autoimmune blistering disease that affects the skin and mucous membranes. It has been...

2006-01-12 22:29:03

NEW YORK (Reuters Health) - Use of inhaled cyclosporine, in addition to other immune-suppressing drugs in pill form, does not help prevent the early rejection of lung transplants, but it does seem to stave off long-term rejection and improve survival, according to a report in The New England Journal of Medicine. Conventional immunosuppressive drugs do not prevent long-term rejection after lung transplantation, lead author Dr. Aldo T. Iacono, from the University of Maryland in...

2005-09-28 16:19:21

People who receive a kidney transplant are nearly four times more likely than the general population to develop melanoma, a rare but deadly form of skin cancer, according to a study led by Christopher Hollenbeak, Ph.D., associate professor, Departments of Surgery and Health Evaluation Sciences, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center. The study, to be published in CANCER, a peer-reviewed journal of the American Cancer Society (Nov.1, 2005 issue), indicates...

2005-09-02 16:04:48

The immunosuppressive drug mycophenolate mofetil, used to prevent rejection of transplanted hearts, kidneys and livers, may also be effective in controlling inflammatory eye diseases, according to a study by researchers at Johns Hopkins' Wilmer Eye Institute. "The drug seemed to be effective even in patients who had failed treatment from other immunosuppressive drugs," says lead author Jennifer E. Thorne, M.D., an assistant professor of ophthalmology. Physicians gave the drug to 84 patients,...